Clinical Trial Update: A Study to Evaluate rhuFab V2 in Subjects With Minimally Classic or Occult Subfoveal Neovascular Macular Degeneration [Phase 3]

View source ↗

Summary

This is a Phase 3 clinical trial completion update for ranibizumab (rhuFab V2) in patients with minimally classic or occult subfoveal neovascular age-related ma…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Age-related Macular Degeneration

Drugs mentioned

• Lucentis (ranibizumab)

Snippet

Sponsor: Genentech, Inc. | Conditions: Macular Degeneration | Phase 3 | Status: COMPLETED